New oral drug shows promise in early cancer trial
NCT ID NCT02937272
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests an experimental drug called LY3200882, taken orally, in people with solid tumors. The main goal is to check safety and find the right dose. Some participants also receive other cancer treatments like chemotherapy or radiation. The study involves 223 adults whose cancer has not responded to standard therapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY3200882 (an experimental oral drug)
What this could lead to
If successful, this could point toward a new treatment option for certain solid tumors.
What could go wrong
This is an early Phase 1 trial focused on safety, not yet proven to work. The drug may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU de Lille
Lille, 59037, France
-
Calvary Mater Newcastle
Newcastle, New South Wales, 2298, Australia
-
Charité Campus Virchow-Klinikum
Berlin, 12203, Germany
-
Greenslopes Private Hospital
Greenslopes, Queensland, 4120, Australia
-
Gustave Roussy
Villejuif, 94805, France
-
Hopital Saint-Louis
Paris, Cedex 10, 75475, France
-
Hospital Clínico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Istituto Clinico Humanitas
Rozzano, Milano, 20089, Italy
-
National Cancer Center Hospital
Chuo-Ku, Tokyo, 104-0045, Japan
-
Ospedale Policlinico Giambattista Rossi, Borgo Roma
Verona, 37134, Italy
-
Princess Margaret Hospital (Ontario)
Lai Chi Kok, Kowloon, Canada
-
St Vincent's Hospital Sydney
Sydney, New South Wales, 2010, Australia
-
University of Louisville
Louisville, Kentucky, 40202, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Universitätsklinikum Würzburg A. ö. R.
Würzburg, Bavaria, 97080, Germany
-
Weill Cornell Medical College
New York, New York, 10021, United States